Bioventus Inc. - Class A Common Stock (BVS)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 488% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 8/9 — financially strong with improving fundamentals
- ROE of 1.9% — below-average profitability
Bioventus Inc. - Class A Common Stock (BVS) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $663 million . Key value metrics: P/E ratio 59.8, P/B ratio 3.51, Piotroski F-Score 8 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Bioventus Inc. - Class A Common Stock — Fundamental Analysis Summary
Bioventus Inc. - Class A Common Stock (BVS) is currently trading 488% above its Graham Number of $1.68, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 59.8x.
On financial health, BVS shows a strong Piotroski F-Score of 8/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 1.9% (sector average: -20.6%), and high leverage with a debt-to-equity ratio of 2.08.
StockPik's composite Value Score for BVS is 75/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BVS reports a high gross margin of 68.3% (sector average: 39.4%) and a modest operating margin of 7.9%.
BVS shows revenue declining at 1% year-over-year, with earnings growing at 168%.